CNS

Psychedelics set to be the revolutionary treatments in pscyhiatry - Thelansis Knowledge Partners

Retrieved on: 
Thursday, February 22, 2024

Availability of psychedelic(s) with few administrations in a year and offering high remission rate could change the treatment pathway for these patients."

Key Points: 
  • Availability of psychedelic(s) with few administrations in a year and offering high remission rate could change the treatment pathway for these patients."
  • According to an interviewed U.S.-based neurologist by Thelansis – "We desperately need disease-modifying treatments for many neurodegenerative conditions.
  • As psychedelics would be beneficial for treatment-nonresponders or severe patients, the commercial opportunities are multiple for in-pipeline psychedelic therapies.
  • What is the probable opportunity for Psychedelics (e.g., psilocybin, MDMA) to address the unmet needs of other TAs?

The 2024 Integrative Healthcare Symposium Delivers Education, Networking and Business to Healthcare Professionals

Retrieved on: 
Tuesday, February 20, 2024

PORTLAND, Maine, Feb. 20, 2024 /PRNewswire-PRWeb/ -- The Integrative Healthcare Symposium, the premier east coast event for holistic and integrative healthcare professionals, hosted more than 1,700 industry professionals February 15-17 at the Hilton Midtown in New York City.

Key Points: 
  • More than 1,700 integrative healthcare practitioners, brand representatives and other professionals traveled to New York City for the annual Symposium
    PORTLAND, Maine, Feb. 20, 2024 /PRNewswire-PRWeb/ -- The Integrative Healthcare Symposium , the premier east coast event for holistic and integrative healthcare professionals, hosted more than 1,700 industry professionals February 15-17 at the Hilton Midtown in New York City.
  • - Christina Henderson, Event Director, Integrative Healthcare Symposium.
  • "Last week we brought together an incredible community of practitioners and healthcare professionals," said Christina Henderson, Event Director, Integrative Healthcare Symposium.
  • The 2025 Integrative Healthcare Symposium will take place February 20-22 at the Hilton Midtown in New York City.

Kenneth R. Pelletier, PhD, MD Receives 2024 Visionary Award at the Integrative Healthcare Symposium

Retrieved on: 
Saturday, February 17, 2024

NEW YORK, Feb. 17, 2024 /PRNewswire-PRWeb/ -- Kenneth R. Pelletier, PhD, MD was today named the 2024 Visionary Award recipient at the Integrative Healthcare Symposium, taking place at the Hilton Midtown in New York City.

Key Points: 
  • NEW YORK, Feb. 17, 2024 /PRNewswire-PRWeb/ -- Kenneth R. Pelletier, PhD, MD was today named the 2024 Visionary Award recipient at the Integrative Healthcare Symposium , taking place at the Hilton Midtown in New York City.
  • — Kenneth R. Pelletier, PhD, MD
    Presented each year at the annual Symposium, the Visionary Award recognizes an industry leader whose contributions have shaped integrative healthcare and paved the way for other practitioners and professionals.
  • Dr. Pelletier will also play an active role at the 2024 Integrative Healthcare Symposium, presenting his session "Change Your Genes – Change Your Life: Epigenetics of Longevity" directly following the award ceremony on Saturday, February 17.
  • The 2024 Integrative Healthcare Symposium is held February 15-17, 2024 in New York City.

Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs

Retrieved on: 
Thursday, February 15, 2024

DALLAS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or “the Company”), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today provided an update on its deprioritized pipeline programs as part of an ongoing effort to help support their further potential development.

Key Points: 
  • DALLAS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or “the Company”), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today provided an update on its deprioritized pipeline programs as part of an ongoing effort to help support their further potential development.
  • Taysha has been working to find ways to advance its deprioritized programs.
  • On November 13, 2023, Taysha terminated its existing loan and security agreement and entered into a new loan and security agreement that provides consent to allow the Company to transfer intellectual property (IP) for several deprioritized programs to third parties in a more efficient manner.
  • “Today’s announcement demonstrates meaningful progress to advance important development work for several deprioritized programs.

Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters

Retrieved on: 
Thursday, February 15, 2024

BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced a publication describing the discovery and initial development of CVN766 in the peer-reviewed journal, Bioorganic & Medicinal Chemistry Letters.

Key Points: 
  • BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced a publication describing the discovery and initial development of CVN766 in the peer-reviewed journal, Bioorganic & Medicinal Chemistry Letters.
  • In the publication titled, “Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist,” the authors describe the development of CVN766 to be over 1,000-fold more selective for the orexin 1 receptor (Ox1R) than the orexin 2 receptor (Ox2R).
  • Dysfunction of this target, Ox1R, is implicated in psychiatric disorders, such as schizophrenia, addictions (including food), and anxieties.
  • “CVN766 has demonstrated high brain permeability, prolonged receptor occupancy, and a pharmacokinetic and safety profile suitable for clinical evaluation across various psychiatric indications,” said Mark Carlton, Ph.D., chief scientific officer for Cerevance.

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity

Retrieved on: 
Thursday, February 15, 2024

GAAP R&D expenses further increased during the twelve month period due to increased stock-based compensation expense related to the accounting for certain performance-based awards during the period.

Key Points: 
  • GAAP R&D expenses further increased during the twelve month period due to increased stock-based compensation expense related to the accounting for certain performance-based awards during the period.
  • A reconciliation of our GAAP to non-GAAP results for the current quarter is included in the tables at the end of this press release.
  • The Company believes the presentation of non-GAAP financial measures provides useful information to management and investors regarding the Company’s financial condition and results of operations.
  • Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures.

Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024

Retrieved on: 
Tuesday, February 13, 2024

Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the fourth quarter and full year 2023 financial and business results on Tuesday, February 27, 2024, at 4:30 p.m.

Key Points: 
  • Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the fourth quarter and full year 2023 financial and business results on Tuesday, February 27, 2024, at 4:30 p.m.
  • Following management’s prepared remarks and discussion of business results, the call will be open for questions.
  • Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call.
  • Following the live call, a replay will be available on the Company's Investor Relations website at www.supernus.com/investors .

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates

Retrieved on: 
Tuesday, February 13, 2024

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the “Company” or “Anebulo”), today announced financial results for the three months ended December 31, 2023, and recent updates.

Key Points: 
  • Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the “Company” or “Anebulo”), today announced financial results for the three months ended December 31, 2023, and recent updates.
  • Second Quarter Fiscal Year 2024 and Subsequent Highlights:
    “Anebulo continues to make progress towards our goal of becoming the first company to have an approved treatment for acute cannabinoid intoxication.
  • “We are pleased to report that the USAN Council has adopted selonabant as the generic name for ANEB-001.
  • Net loss in the second quarter of fiscal 2024 was $2.7 million, or $(0.11) per share, compared with a net loss of $3.8 million, or $(0.15) per share, in the second quarter of fiscal 2023.

Corero Network Security Pioneers the Next Step in DDoS Protection with SmartWall ONE for 400G Networks

Retrieved on: 
Tuesday, February 13, 2024

MARLBOROUGH, Mass., Feb. 13, 2024 /PRNewswire/ -- Corero Network Security (LON: CNS), the specialists in distributed denial of service (DDoS) protection solutions, today announced that it has extended the capabilities of its leading DDoS protection solution, SmartWall ONE, to include additional support for 400G-connected DDoS detection, mitigation, and protection from the edge to the network core and demonstrates Corero's ongoing investment in developing state-of-the-art DDoS protection.

Key Points: 
  • MARLBOROUGH, Mass., Feb. 13, 2024 /PRNewswire/ -- Corero Network Security (LON: CNS), the specialists in distributed denial of service (DDoS) protection solutions, today announced that it has extended the capabilities of its leading DDoS protection solution, SmartWall ONE , to include additional support for 400G-connected DDoS detection, mitigation, and protection from the edge to the network core and demonstrates Corero's ongoing investment in developing state-of-the-art DDoS protection.
  • Organizations are embracing the use of 400G to reduce the number of 100G interconnects.
  • Corero SmartWall ONE meets this challenge with a family of 400G-connected DDoS solutions that can quadruple the performance density and halve the power budget of many deployments.
  • Our expertise in DDoS protection, coupled with prudent technology investment, ensures that our products will remain at the forefront of modern cybersecurity solutions.

Enigma Biomedical - USA Announces Appointment of Hartmuth Kolb, PhD as Chief Scientific Officer

Retrieved on: 
Tuesday, February 13, 2024

Enigma Biomedical USA (EB) today announced the appointment of Hartmuth Kolb, PhD as Chief Science Officer (CSO).

Key Points: 
  • Enigma Biomedical USA (EB) today announced the appointment of Hartmuth Kolb, PhD as Chief Science Officer (CSO).
  • Dr. Kolb’s passion for innovation and scientific rigor has driven his extensive career and broad recognition.
  • He will join Enigma at the beginning of March, 2024.
  • In his 10 year tenure at Johnson & Johnson Innovative Medicine, he served as the Vice President, Neuroscience Biomarkers and Global Head of Imaging.